

Press Release

## Alkem reports 11% revenue growth, 22% rise in net profit in Q1 FY26.

**Mumbai, August 12, 2025:** Alkem Laboratories Ltd. today announced its standalone and consolidated financial results for the first quarter ended June 30, 2025. The Board of Directors took record of these results at its meeting held in Mumbai today.

### Key Financial Metrics



### Key highlights of Q1 FY26 financial performance

- Total Revenue from Operations was ₹33,711 million, with YoY growth of 11.2%.
  - India sales were ₹22,650 million, YoY growth of 12.0%.
  - International sales were ₹10,539 million, with YoY growth of 8.9%.
- Earnings before Interest, Tax, Depreciation, and Amortisation (EBITDA) were ₹7,391 million, resulting in an EBITDA margin of 21.9% vs. 20.1% in Q1 FY25. EBITDA grew by 21.4% YoY.
- R&D expenses for Q1 FY26 were ₹1,184 million, or 3.5% of total revenue from operations, vs. ₹1,257 million in Q1 FY25 at 4.1% of total revenue from operations.
- Profit before tax before exceptional items was ₹7,581 million, YoY growth of 22.4%.
- Net Profit (after Minority Interest) was ₹6,643 million, YoY growth of 21.8%.
- According to IQVIA (SSA) data, for Q1 FY26:
  - The Company registered a growth of 9.7% YoY compared to the Indian Pharmaceutical Market (IPM), which grew by 8.5%.
  - We achieved strong overall volume growth of 2.9%, outperforming the IPM volume growth of 1.5% by 140 basis points.

*Commenting on the Q1 FY26 results, Dr. Vikas Gupta, CEO of Alkem, said, “Q1 FY26 marked a strong start to the year, with healthy growth across both our domestic and international markets. Our performance was driven by strong topline growth and an improved gross margin, which resulted in a better EBITDA profile. These results reflect the disciplined execution of our strategy, focused investments, and a deliberate pivot toward value-accretive products and markets with a sharper focus on EBITDA. We are strategically accelerating our focus on the non-US business segment by strengthening our presence in high-potential non-US markets and capturing new opportunities that align with our long-term growth ambitions.”*

## Operational Highlights

### Domestic Business – Q1 FY26 Key Highlights

- India sales were ₹22,650 million, YoY growth of 12.0%.
- The contribution of domestic sales to total sales in Q1 FY26 was 68.3% vs. 67.6% in Q1 FY25.
- As per IQVIA (SSA) data, during the quarter, we have outperformed IPM in seven therapies: Gastrointestinal grew by ~1.6X, VMN ~2.3X, Pain ~1.4X, Anti-Diabetics ~1.4X, Neuro/CNS ~1.2X, Respiratory ~1.4X, and Derma ~1.1X.

### International Business – Q1 FY26 Key Highlights

- International sales were ₹10,539 million, YoY growth of 8.9%.
- US sales were ₹6,982 million, YoY growth of 8.8%.
- US business sales contributed 21.0% to total sales in Q1 FY26.
- Non-US sales were ₹3,556 million, YoY growth of 9.1%.
- Non-US business sales contributed 10.7% to total sales in Q1 FY26.
- During the Q1 FY26, for the US market, the Company filed its first BLA, received 05 ANDA approvals (including 02 tentative approvals) and launched 03 products.
- As of June 30, 2025, the Company had filed 185 ANDAs, 02 NDAs and 01 BLA with the USFDA. It has received approvals for 160 ANDAs (including 15 tentative approvals) and 02 NDAs.

**About Alkem:** Alkem Laboratories Ltd. is the fifth-largest pharmaceutical company in the Indian market, with a legacy spanning over 50 years of providing high-quality medicines to patients. It holds a dominant position in the therapy areas of anti-infectives, gastrointestinal disorders, pain management, and supplements. It also has a growing portfolio of products in chronic therapies, including diabetes, neurology, dermatology, and urology. It has 18 state-of-the-art manufacturing facilities and cutting-edge research and development (R&D) centres to develop and manufacture generic formulations, active pharmaceutical ingredients (APIs) and biosimilars. Apart from India, the company has a meaningful presence in the US, Latin America, Australia, and several other Asian countries. “Inspiring Healthier Lives” is at the core of the organisation's values and culture, reinforcing its steadfast commitment to improving global health. For more information, please visit [www.alkemlabs.com](http://www.alkemlabs.com) and follow us on [LinkedIn](#), [Instagram](#), and [Facebook](#).

### Contact

#### Investors:

Purvi Shah – Head of Investor Relations  
+91 84337 00890  
[purvi.shah@alkem.com](mailto:purvi.shah@alkem.com)  
+91-22-3982 9999 Ext: 9447

#### Media:

Isha Trivedi  
+91 98925 90003  
[alkemcorpcomm@alkem.com](mailto:alkemcorpcomm@alkem.com)  
+91-22-3982 9999 Ext: 9672

**Invite for Q1 FY26 Conference Call at 5.00 pm IST, August 12, 2025**

**Mumbai, August 07, 2025:** Alkem Laboratories Ltd. (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) will hold a conference call for investors and analysts on Tuesday, August 12, 2025, from 5:00 pm to 6:00 pm IST to discuss its Q1 FY26 financial results. The call will follow the announcement of the Company's Q1 FY26 financial results on Tuesday, August 12, 2025.

**Alkem Laboratories Ltd. will be represented on the call by:**

Dr. Vikas Gupta – CEO  
Mr. Nitin Agrawal – CFO

**Motilal Oswal Securities Ltd. will host the call.**

**Details of the conference call are as follows:**

**Time:** 5:00 pm IST (GMT + 5:30) on Tuesday, August 12, 2025.

**Dial in Details:**

India: +91 22 6280 1149 / +91 22 7115 8050

**International Toll-Free**

USA	: 1 866 746 2133
UK	: 0 808 101 1573
Singapore	: 800 101 2045
Hong Kong	: 800 964 448

**Express Join with Diamond Pass**

<https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=9357875&linkSecurityString=46351d096d>

You are requested to dial in 10 minutes ahead of the

**Purvi Shah / Isha Trivedi**

Investor Relations / Media  
Alkem Laboratories Ltd.

Mobile: +91 84337 00890 / 98925 90003

Tel.: +91 22 3982 9999 Ext: 9447

E-mail: [purvi.shah@alkem.com](mailto:purvi.shah@alkem.com) /

[isha.trivedi@alkem.com](mailto:isha.trivedi@alkem.com)

**Tushar Manudhane**

Institutional Research Analyst - Healthcare  
Motilal Oswal Securities Ltd.

Tel.: +91 22 6129 1536 / +91 82911 38039

E-mail:

[Tushar.Manudhane@motilaloswal.com](mailto:Tushar.Manudhane@motilaloswal.com)